Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic. A randomised study

Guri Holmen Gundersen,1 Tone M Norekval,2,3 Hilde Haugberg Haug,1 Kyrre Skjøtta,1 Jens Olaf Kleinau,1 Torbjorn Graven,1 Harvad Dalen1,4

ABSTRACT

Objectives Medical history, physical examination and laboratory testing are not optimal for the assessment of volume status in heart failure (HF) patients. We aimed to study the clinical influence of focused ultrasound of the pleural cavities and inferior vena cava (IVC) performed by specialised nurses to assess volume status in HF patients at an outpatient clinic.

Methods HF outpatients were prospectively included and underwent laboratory testing, history recording and clinical examination by two nurses with and without an ultrasound examination of the pleural cavities and IVC using a pocket-size imaging device, in random order. Each nurse worked in a team with a cardiologist. The influence of the different diagnostic tests on diuretic dosing was assessed descriptively and in linear regression analyses.

Results Sixty-two patients were included and 119 examinations were performed. Mean±SD age was 74±12 years, EF was 34±14%, and N-terminal pro-brain natriuretic peptide (NT-proBNP) value was 3761±3072 ng/L. Dosing of diuretics differed between the teams in 31 out of 119 consultations. Weight change and volume status assessed clinically with and without ultrasound predicted dose adjustment of diuretics at follow-up (p<0.05). Change of oedema, NT-proBNP, creatinine, and symptoms did not (p>0.10). In adjusted analyses, only volume status based on ultrasound predicted dose adjustments of diuretics at first visit and follow-up (all ultrasound p≤0.01, all other p>0.2).

Conclusions Ultrasound examinations of the pleural cavities and IVC by nurses may improve diagnostics and patient care in HF patients at an outpatient clinic, but more studies are needed to determine whether these examinations have an impact on clinical outcomes.

Trial registration number NCT01794715.

INTRODUCTION

In spite of optimal medical therapy, heart failure (HF) may progress with unpredictable episodes of worsening. Fluid retention (hypervolaemia) is a major cause of worsening HF.1–3 Haemodynamic disturbances leading to acute decompenated HF may start weeks before the actual onset of typical HF.1 In the early stages of decompensation effective and more aggressive therapy could potentially prevent deterioration and hospitalisation.3 Estimation of volume status is crucial because achieving euvolaemia in HF patients is an important goal of therapy.1 Diuretics are superior for achieving and maintaining euvolaemia but frequently there is a very narrow window of optimal volume status.5 6 Hyper- and hypovolaemia may lead to decompenated HF and organ failure caused by inadequate perfusion.2

Traditionally, the cornerstone of the patient’s volume status assessment in the outpatient HF clinic is the evaluation of symptoms, monitoring of weight and peripheral oedema, and blood tests including creatinine and natriuretic peptides, but these are neither sensitive nor specific with respect to detecting volume status.3 7–10 Ultrasound (US) is a sensitive and specific tool to estimate volume status, by assessment of the inferior vena cava (IVC) and the pleural cavities, and may have a crucial influence.10–14 The development of high quality, low cost pocket-size imaging devices (PSID) has promoted diagnostic US by non-experts.15–17 It is not known if the PSIDs could be used as a tool for monitoring volume status and guiding treatment in HF patients. We have recently shown that specialised nurses in an HF clinic can perform point of care US for quantification of pleural effusion and the dimension and inspiratory collapsibility of the IVC, with a high agreement with cardiologists using high-end equipment.16 Specialised nurses have a growing role in diagnostics and follow-up of outpatient HF patients,18 and adding point of care US diagnostics to the nurses’ consultations may improve care. Thus, we aimed to study the clinical influence of focused US of the pleural cavities and IVC performed by specialised nurses, to assess volume status in patients with HF in a nurse-led outpatient clinic.

PATIENTS AND METHODS

Study population and design

Patients allocated to the outpatient HF clinic at the non-university Levanger Hospital, Norway, 15 April to 21 June 2013 were eligible for inclusion. Written informed consent was obtained. The study was registered at ClinicalTrials.gov (ID: NCT01794715) and approved by the Regional Committee for Medical and Health Research Ethics (REK 2013/257), and conducted according to the Second Declaration of Helsinki. Follow-up data are shown in online supplementary results.

Figure 1 shows the patient flow and the crossover design of the study, and the basis for the statistical analyses. At each visit the patients were examined by two separate specialised nurses both

To cite: Gundersen GH, Norekval TM, Haug HH, et al. Heart 2016;102:29–34.
with and without point of care US. The sequence of the examinations with and without US, as well as which personnel performed US, was in each case randomised by draw. Each of the two nurses were blinded to the information from the other nurse. For each visit the nurse worked in a team with a cardiologist (one of four) in a random order. After the patients had been examined by one of the nurses at each study visit, they were examined by the second nurse, either with or without US opposite to the first nurse. Further details on the training of the nurses have been recently published.16

The specialised nurses recorded the medical history and performed a clinical examination with respect to physical signs of fluid retention or depletion at every visit to the HF clinic. During each patient visit, one of the nurses carried out point of care US of the pleural cavities and IVC to assess volume status as an adjunct to the clinical examination, and the other nurse completed the medical history recording and the clinical examination without point of care US. The nurses discussed their findings with respect to adjusting therapy with a cardiologist in a random way (figure 1). The therapeutic decisions made by the ‘non-US’ team were applied for the study purpose only and the patients were treated according to the decision of the team which included US in the consultation.

Only the team (nurse and cardiologist) who included the US examination had access to the US findings. If the patient later visited the HF clinic for follow-up, the US examination was performed by the nurse only and no echocardiography was performed by a cardiologist. At follow-up visits, both teams had access to previous US findings.

Blood samples were drawn from the participants at baseline and follow-up. The blood samples were analysed at the hospital’s IEC 17025 accredited laboratory for assessment of haemoglobin, sodium, potassium, international normalised ratio (INR), uric acid, creatinine, estimated glomerular filtration rate (eGFR), and N-terminal pro-brain natriuretic peptide (NT-proBNP).

**History recording and clinical examination to assess volume status**

The history recording included assessment of the patients’ symptoms according to New York Heart Association (NYHA) classification by both nurses. The patients were assigned NYHA class I–IV where I refers to no symptoms and IV refers to symptoms at rest. The clinical examination by the two specialised nurses was performed in a random order in separate rooms.

The clinical examination included: ECG, measurement of blood pressure and heart rate, weight control, and assessment of peripheral oedema. Weight change since hospital discharge or a previous visit in the HF clinic was classified as weight loss or weight gain if it was reduced or increased by >1.5 kg and as no change in between. Peripheral oedema was graded as no oedema, ankle oedema, leg oedema or oedema above the knee. No cardiac auscultation or further clinical assessment was performed by the nurses.

**Point of care US examinations by the nurses to assess volume status**

The US examination was performed using the Vscan system (GE Ultrasound, Horten, Norway). With the patient in the supine position the dimensions of the IVC were measured distally to the inlet of the hepatic vein in the sagittal plane. The complete respiratory cycle was recorded, including sniff.

---

**Figure 1** Flow chart of the study. All participants underwent full cross-over with examinations with and without ultrasound (US) in a random order at every study visit. The sequence was randomised by draw both at first and follow-up study visits. Echocardiography for validation was only performed at first visit (N=62). Both the teams with and without access to US made therapeutic decisions based on all available information (usual care±US examination). N, number of visits; NYHA, New York Heart Association; US(−), without access to ultrasound; US(+), with access to ultrasound.

| Medical history (NYHA-class) (N=119) | Clinical examination (oedema) (N=119) | Volume status (medical history + clinic + laboratory ± US) (N=119) | Diuretic dosing (medical history + clinic + laboratory ± US) (N=119) |
| --- | --- | --- | --- |
| TeamUS(−) vs TeamUS(+) | NurseUS(−) vs NurseUS(+) | NurseUS(−) vs NurseUS(+) | TeamUS(−) vs TeamUS(+) |

---

30 Gundersen GH, et al. Heart 2016;102:29–34. doi:10.1136/heartjnl-2015-307798
Trailing-to-leading edge (ie, the inner diameter) was used. The collapsibility index of the IVC (IVCCD) was calculated as the difference between end-expiratory and end-inspiratory dimension divided by the end-expiratory dimension. The IVC was divided into five categories by adding the score for the maximal dimension and collapsibility. For end-expiratory dimension score 1, 2 and 3 refer to IVCCD <1.7 cm, 1.7–2.1 cm and >2.1 cm, respectively, and for the IVCCD score 1, 2 and 3 refer to ≥50%, 35–50% and <35%, respectively.

With the patient in a sitting position both hemithoraces were examined with the US transducer placed intercostally from the paravertebral to the axillary lines. The presence of pleural effusion was diagnosed by the appearance of an echo-free space between the diaphragm and the lung and the amount was measured between the diaphragm and the lung surface in the middle between the transducer and the mediastinum.

Additional data are provided in the online supplementary methods.

**Influence on treatment**
The nurses classified the patients’ volume status based on the complete examination (with or without US) as hypovolaemic, euvoalaemic or hypervaolaemic. Any decisions regarding diuretic adjustment were made in cooperation with the cardiologist on the basis of all available data from both the laboratory tests, and clinical and US examinations. Dosing of diuretics was classified as: −1, reduced; 0, unchanged; or +1, increased diuretic dose.

**Validation by high-end echocardiography**
Reference echocardiography was performed by one of four experienced cardiologists using a Vivid 7 scanner (GE Ultrasound) immediately after the US examination by the nurses and included assessment of the IVC and pleural cavities as described above. The high feasibility and high reliability of the US examinations by the nurses is comprehensively described in a recent publication.

**Statistical analysis**
Normal distributed data are presented as mean±SD if not described elsewhere. The comparison of different clinical and US indices for assessing HF (ie, symptoms, oedema, dimension or grading of pleural effusion, assessment of volume status) between the nurses, nurses and cardiologists, or between the two teams was analysed by Spearman’s or Pearson’s correlation coefficient, as well as kappa statistics. Data are presented as r (95% CI) with the 95% CI computed using bootstrapping. Predictors of diuretic therapy were tested in uni- and multivariate linear regression analyses with dose adjustments (reduced =−1, unchanged =0 or increased =+1 intensity) used as dependent variables and the different predictors of clinical interest to test were included as covariates. In sensitivity analyses using logistic regression models, predictors for increased or decreased diuretic dosing were tested. In addition, the clinical influence of EF and whether the patient was seen by a cardiologist was tested. A two-sided p value <0.05 was considered statistically significant. All the statistical analyses were performed using SPSS for Windows (V21, SPSS, Inc).

**RESULTS**

**Study population**
The clinical characteristics of the 62 study participants are shown in table 1. Mean±SD age was 74±12 years, and EF and NT-proBNP were 54±14% and 3761±3072 ng/L, respectively. The main reasons for not using angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) at study entry was renal failure in 27%, hypotension in 36%, and diastolic HF in 9%, while in the rest of the patients such medications were started later. The distribution of pleural effusion was not associated with EF (p=0.10). The high morbidity and mortality of the participants is shown in the online supplementary results.

**Reliability of medical history, clinical signs, physical findings, and US**
Table 2 shows the relatively poor agreement between medical history, clinical signs and physical findings assessed by the two specialised nurses. The nurses agreed in the assessment of volume status in 75 out of 119 paired consultations. The two teams (nurses and cardiologists) agreed in somewhat more (89 out of 119) paired consultations regarding diuretic dosing.

---

**Table 1 Clinical characteristics of the 62 study participants**

| Age, years | Mean±SD (range) |
|------------|-----------------|
| Women, n (%) | 74±12 (35–91) |
| Body mass index (kg/m²) | 28.3±5.5 (18.6–45.8) |
| Systolic blood pressure (mm Hg) | 121±23 (80–171) |
| Diastolic blood pressure (mm Hg) | 71±14 (50–107) |
| Sinus rhythm, n (%) | 25 (40)* |
| Heart rate, bpm | 79±21 (51–140) |
| NT-proBNP, ng/L | 3761±3072 (90–9999) |
| eGFR, mL/min/1.73 m² (Cockcroft-Gault) | 34±15 (12–85) |
| NYHA functional class, median (25th and 75th centile) | II (I and III)* |
| Cause of heart failure; ischaemic, n (%) | 31 (50)* |
| Cause of heart failure; mainly diastolic, n (%) | 15 (24)* |
| Using diuretics, n (%) | 56 (90)* |
| Using β-blockers, n (%) | 49 (79)* |
| Using ACEI or ARB, n (%) | 37 (60)* |
| EF (%) | 33.7±13.6 (7–64) |
| LV end-diastolic dimension, mm | 56±11 (22–80) |
| LV end-diastolic volume, mL | 136±76 (35–398) |
| Mitral early inflow, cm/s | 83±25 (39–144) |
| Mitral early inflow deceleration time, ms | 176±47 (82–263) |
| Any pleural effusion, n (%) | 26 (42)* |

*Data not presented as mean±SD (range), and thus specified.

ACEI, angiotensin-converting enzyme inhibitor; ARB; angiotensin receptor blockers, eGFR, estimated glomerular filtration rate; n, number; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA; New York Heart Association.

---

**Table 2 Agreement of different indices relevant for heart failure assessment in 119 crossover consultations by the two nurses**

| NYHA class | Agreed, n (%) | Agreement (κ) |
|------------|---------------|---------------|
| Peripheral oedema | 88 (74) | 0.59 |
| Volume status | 75 (63) | 0.38 |
| Diuretic treatment* | 88 (74) | 0.46 |

*Agreement is between the two teams (nurse and cardiologist with and without focused ultrasound examination. Agreed describes the number (%) with exact match, while the agreement by Spearman correlation statistics takes weighted difference into account.

The table shows the fair to substantial agreement between the two nurses of different indices relevant for heart failure assessment (all p<0.001). Volume status assessed by clinical findings, laboratory tests and with or without focused ultrasound examination. Agreed describes the number (%) with exact match, while the agreement by Spearman correlation statistics takes weighted difference into account.

*Agreement is between the two teams (nurse and cardiologist with and without access to ultrasound, respectively).

NYHA, New York Heart Association; r, correlation; κ, kappa statistics.
Figure 2 shows the high correlations of the nurses’ measurements of the dimension of the IVC and quantification of the pleural effusion with the reference measurements. During the first visit pleural effusion was detected in 36 pleural cavities in 23 patients by the nurses and in 39 pleural cavities in 26 patients by reference echocardiography performed by the cardiologists.

Predictors of diuretic therapy
The online supplementary table shows the characteristics and clinical findings of 17 follow-up visits where diuretic treatment differed between the teams (with and without US for the assessment of volume status). It is shown that an increase of pleural effusion revealed with PSID resulted in an increase of diuretic therapy, and correspondingly a reduction of pleural effusion resulted in a decrease of diuretic therapy.

Table 3 shows predictors of diuretic therapy by the first study visit and by follow-up. At the first visit, volume status assessed as cumulative information of clinical and laboratory tests, as well as assessment of IVC or the pleural cavities by US, predicted diuretic dosing, but as standalone indices neither clinical nor laboratory tests predicted diuretic dosing. By the follow-up visits, weight change and all ultrasonographic indices were also significant predictors of dose adjustment of diuretic therapy, whereas change in the distribution of oedema, NT-proBNP, creatinine or change of NYHA class did not predict diuretic dose adjustment (all p≤0.10). In analyses adjusted for all described variables, only volume status based on US predicted change of diuretic dosing when this variable was entered at the first step and the non-US variables were entered stepwise thereafter (all US p≤0.01, all other p≥0.2). Whether or not the cardiologist performed echocardiography as reference imaging (only at first visit) did not significantly influence the result (p=0.12).

The semi-quantitative classification of pleural effusion and IVC correlated well with volume status (both r=0.67, p<0.001). At first study visit both the findings of any pleural effusion or a dilated IVC with reduced collapsibility with semi-quantitative score ≥5 were associated with increased mortality with 2 year follow-up (p=0.07 and p<0.001, respectively) (see online supplementary results and figure).

During mean follow-up of 38 days only three (5%) patients were admitted due to any HF related events. At 1 year HF readmissions were 25.8%. Additional data are presented in the online supplementary results.

DISCUSSION
In this study of patients in an outpatient HF clinic, specialised nurses were able to perform and interpret point of care US examination of the IVC and the pleural cavities to assess volume status with excellent quality, in contrast to the poor inter-observer agreement of medical history, clinical signs and physical examination. In regression analyses, the estimated volume status based on US predicted dose adjustments of diuretics significantly better than any other tool used to assess patients’ volume status and guide therapy.

Patients with HF are encumbered with substantial morbidity and this was also the case in this study population. Pleural effusion is closely related to congestion and decompensation among HF patients and may be difficult to detect both by clinical examination and chest X-ray. However, pleural effusion is easily assessable by US and at first visit pleural effusion was present in 42% of the patients. Detection of newly developed pleural effusion in HF patients may indicate that the patients need intensified treatment. As shown by the basic characteristics the study population is quite similar to populations in other HF clinics, and it is reasonable to believe that our frequent finding of pleural effusion may be present in most HF populations.

The present study shows poor to moderate correlation between the nurses regarding medical history and physical signs. Although the clinical assessment of peripheral oedema and classification of NYHA class are commonly used in the HF clinic, neither of them has been proven to be sufficiently objective, reliable or sensitive. Symptoms and signs of fluid retention may be minimal and unspecific, and even attenuated by a low level of daily activity. In addition, comorbidity and venous insufficiency may be misleading.

However, in the present study neither weight change, oedema, blood tests nor NYHA class appear optimal when it comes to monitoring of volume status. Monitoring the data may perform better than discrete values. However, the routine use of US may improve the assessment of volume status. The agreement between the teams (nurse and cardiologist) regarding volume status was numerically somewhat better compared to the agreement between the nurses, respectively.

![Figure 2](image-url)
In a recent study, we showed the high correlations of quantitative measurements of pleural effusion and the dimension of IVC between specialised nurses and cardiologists. This result is in line with findings of other groups with more or less inexperienced users after dedicated training.

The robustness observed by the pocket-sized imaging of the pleural cavities and the IVC may be related to the fact that these measurements are not too difficult to obtain with high accuracy. This shows that the training of the nurses was sufficient and in line with recent recommendations, and that the applied US assessment seems attractive for the monitoring of patients with HF.

To our knowledge, no other study has shown the clinical influence of routinely including focused US of the pleural cavities and IVC, performed by specialised nurses, to assess volume status and guide treatment in an outpatient HF clinic. However, whether the implementation of focused US imaging of the pleural cavities and the IVC to assess volume status for guidance of therapy will exert an influence on mortality and morbidity remains to be shown. In this study, given the high morbidity of the HF patients, only three patients (5%) were hospitalised during the study period (mean 38 days). This appears to be a low number compared to published data where readmission rates at 30 days were 15–50%. The hospitalisation rate in the present study is in line with the results from studies where implantable devices for haemodynamic monitoring have been used to guide treatment.

Previous studies have shown that US assessment of the IVC and pleural cavities is able to predict right atrial filling pressures, predict outcome, and may very well be suited for the monitoring of HF patients. Pleural effusion is frequently present in asymptomatic worsening of HF, with minimal appearance of other HF-related signs. Implementing the described US examination may have an important influence on therapeutic decision making and potentially also the patient’s outcome. Natriuretic peptides have a high specificity for diagnosing HF, provide important prognostic information, and are able to guide therapy in HF patients. However, their performance may be inferior to US examinations for individual monitoring for follow-up of HF patients. Natriuretic peptide guided therapy may be most useful to optimise the doses of β-blockers and ACEIs.

The high prevalence of pleural effusion among HF patients, the high feasibility and accuracy of US examination by nurses, and the high availability and low cost of the PSID may result in a high level of clinical gain by implementing focused US for the assessment of volume status in HF patients. Restricting such diagnostic examinations only to physicians may limit the clinical gain.

Limitations
This study was a single centre study. The major limitations are the lack of a gold standard for assessing volume status and the lack of clinical endpoints. The US findings of significant pleural

### Table 3 Predictors of diuretic therapy at first visit and follow-up study visits

| Covariates                        | First study visit |          |          | Follow-up study visits |          |          |
|-----------------------------------|-------------------|----------|----------|------------------------|----------|----------|
|                                   | β                  | R²       | p Value  | β                      | R²       | p Value  |
| Volume status included US         | 0.576              | 0.375    | <0.001   | 0.575                  | 0.391    | <0.001   |
| IVC category                      | 0.290              | 0.207    | <0.001   | 0.139                  | 0.62     | <0.001   |
| IVC dimension                     | 0.263              | 0.155    | 0.01     | 0.302                  | 1.86     | <0.001   |
| Pleural effusion                  | 0.109              | 0.09     | 0.01     | 0.885                  | 1.3      | <0.01    |
| Volume status without US          | 0.284              | 0.75     | 0.03     | 0.349                  | 1.4      | <0.01    |
| Weight                            | 0.002              | 0.4      | 0.63     | 5.43                   | 1.2      | <0.01    |
| Oedema                            | 0.107              | 0.2      | 0.27     | 0.126                  | 2.7      | 0.22     |
| NYHA class                        | 0.187              | 2.6      | 0.21     | 0.168                  | 3.9      | 0.14     |
| Creatinine                        | -0.001             | 0.5      | 0.6      | -0.430                 | 2.0      | 0.29     |
| NT-proBNP                         | 0.000              | 0.5      | 0.10     | 0.018                  | 1.6      | 0.35     |

β coefficients, coefficient of determination (R²) and level of significance assessed in univariate model with ‘diuretic therapy’ as reduced (−1), unchanged (0) or increased (+1) as dependent variable and the listed covariates. By first study visit (n=62) oedema, NYHA class, weight, creatinine, and NT-proBNP were included as absolute values as described in the Methods section. By follow-up study visits the latter three covariates were included as relative change since last contact, and oedema and NYHA class were included as absolute changes, respectively. Pleural effusion was included as sum of semi-quantitative classification at first contact and as the average change of left and right pleural cavity graded as: −1, reduced measure >1 cm; +1, increased measure >1 cm; or 0 when change was <1 cm.

ICV, inferior vena cava; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; US, ultrasound assessment of the pleural cavities and IVC.

### Key messages

**What is already known on this subject?**
Fluid retention (hypervolaemia) is a major cause of morbidity and readmissions and may start weeks before the actual onset of typical heart failure (HF) symptoms. Evaluation of symptoms, monitoring of weight and peripheral oedema, blood tests and chest X-ray are not sensitive to detecting early changes in volume status.

**What might this study add?**
We have shown the clinical influence of routinely including focused ultrasound of the pleural cavities and the inferior vena cava, performed by specialised nurses, to assess volume status and guide treatment in an outpatient HF clinic. In this study nurses were able to perform and interpret point of care ultrasound to assess volume status with excellent quality, allowing for improvement in available information for the caregiving physician.

**How might this impact on clinical practice?**
Implementation of point of care ultrasound to assess volume status may improve diagnostics, and thus follow-up and prognosis among heart failure patients. However, whether this will have an influence on mortality and morbidity remains to be shown.
effusion or a very narrow IVC with a very high CI may significantly alter decisions regarding diuretic dosing and this may have influenced the result. Further studies investigating the influence of this methodology on endpoints such as readmission rates and mortality are warranted.

CONCLUSION AND IMPLICATIONS
Focused US examinations of the pleural cavities and IVC among HF patients in an outpatient clinic performed by nurses significantly predicted dose adjustments of diuretics compared to standard care. Acknowledging the lack of a gold standard for assessing volume status, we conclude that implementing point of care US appears attractive for optimising the management of HF patients beyond standard clinical care, but further studies are needed to determine whether point of care US improves clinical outcomes.

Contributors All the authors fulfil all the listed criteria below: (1) conception and design or analysis and interpretation of data, or both; (2) drafting of the manuscript or revising it critically for important intellectual content; (3) final approval of the manuscript submitted.

Funding The Nord-Trøndelag Health Trust, Norway, funded this study.

Competing interests HD holds position at the Medical Imaging Laboratory, NTNU, a Centre of Research-based Innovation that is funded by the Research Council of Norway and industry. One of the industry partners is GE Ultrasound. The Centre had a total budget of 1.24 million NOK for the 8-year period 2007–2014, and the contribution from GE Virgmed Ultrasound to this budget is approximately 7 million NOK (6%).

Patient consent Obtained.

Ethics approval Regional Committee for Medical and Health Research Ethics.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Additional unpublished data regarding patients’ QoL are available, though not analysed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
1. Pang PS. Pathophysiology of volume overload in acute heart failure syndromes. Congest Heart Fail 2010;16:51–6.
2. Albert NM. Fluid management strategies in heart failure. Crit Care Nurse 2012;32:20–32.
3. von Lueder TG, Krum H. Current modalities for invasive and non-invasive monitoring of volume status in heart failure. Heart 2012;98:967–73.
4. Desai AS, Stevenson UW. Rehospitalization for heart failure: predict or prevent? Circulation 2012;126:501–6.
5. Faris RF, Flaher M, Purcell H, et al. Diuretic treatment, chronic heart failure. Cochrane Library. 2012.
6. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 2012;33:1787–847.
7. Fonseca C, Morais H, Mota T, et al. The diagnosis of heart failure in primary care: value of symptoms and signs. Eur J Heart Fail 2004;6:795–800.
Supplemental Methods:

Study population and design:
All patients were included after providing written informed consent. The exclusion criteria were inability or unwillingness to provide informed consent and HF worsening requiring hospital admission at entry.

They were informed that they could withdraw from the study at any time. All patients eligible for inclusion gave their consent to participate in the study and none withdrew their consent.

The reference echocardiographic examination was performed by the cardiologist who was randomized to follow-up the nurse who already had carried out an US examination of the patient. The cardiologist was blinded to the result of the examination performed by the nurse and did not perform any history taking or clinical examination.

History recording and clinical examination to assess volume status
Furthermore, patients were interviewed about medication, potential side effects of the drugs, as well as daily activities. The patients were advised on water and salt restriction, if relevant, as well as informed about the drugs and therapeutic choices.

Pocket size-ultrasound examination by the nurses to assess volume status
The device weight is 390 g, including the phased-arrayed probe and is a low-cost scanner. The device offers two-dimensional grey scale and colour Doppler imaging, and dimension can be measured online on the device. The bandwidth with range of 1.7-3.8 MHz is automatically adjusted. The length of recordings of other structures is predefined and limited to 2 seconds, if the automatic algorithm does not detect cyclicity (i.e. left ventricular recordings). Patient identification is allowed by voice recording and automatically assessed examination number.

All images and recorded loops were saved on the device’s micro-SD card and later transferred to a computer by commercial software (Gateway; GE Vingmed Ultrasound).

The IVC was measured distally to the inlet of the hepatic vein in the sagittal plane.
Loops containing the complete respiratory cycle were frozen and the nurses scrolled manually on the PSID to measure the maximal IVC diameter (end-expiratory) and minimum IVC diameter (end-inspiratory (sniff)).
The hemithoraces were assessed with patient in sitting position with respect to pleural effusion. The diaphragm was identified on both sides by using the liver and spleen as landmarks. Pleural effusion located in the costodiaphragmatic angle only, was assessed semi quantitatively and due to the small amount of fluid classified as insignificant. By larger amount of effusion the dimension between the diaphragm and the lung surface was measured in the middle between the transducer and the mediastinum. If the atelectatic lung bulged into the effusion, the extent of the effusion was measured just medially to the protruding edge of the lower lung lobe. The amount of pleural effusion was classified as no pleural effusion when not present, insignificant when present in the costodiaphragmatic recess only, small to moderate amount when the described dimension was <3 cm and significant when the measurement was ≥3 cm.

**Validation by high-end echocardiography**

The high feasibility and high reliability of the US examinations by the nurses is comprehensively described in a recent publication.

The reference echocardiography was performed by one of four cardiologists blinded to known clinical and imaging results. A Vivid 7 scanner (GE Vingmed Ultrasound, Horten, Norway) was used. The dimension of the IVC and pleural effusion were measured as described for pocket-size US.

The echocardiographic examination was performed with the patient placed in a left lateral supine position. Ejection fraction (EF) and left ventricular (LV) volumes were calculated based on tracing of the endocardial borders in the 4-chamber and 2-chamber views and the LV dimension was measured in the parasternal long axis motion mode recordings. Mitral inflow indices were measured by pulsed wave Doppler with the sample volume at the
tip of the mitral leaflets. These measurements are incorporated in the basic characteristics only. Based on the echocardiograms and the medical history the cardiologist determined the main cause of the patient’s heart failure.

Statistical analysis

The kappa and correlation statistics were interpreted as “<.2”; slight agreement, “.21-.4”; fair agreement, “.41-.6”; moderate agreement, “.61-.8”; substantial agreement and “>.8”; almost perfect agreement.

Sample size of > 55 participants was estimated by expecting difference in classification of volume status of 10 percentage points (with an error of 8 percentage point). Power estimates were calculated by Sample Power (version 3; SPSS Inc., Chicago, IL, USA).
Supplementary Results:

Study population

Of the participants 24% had HF with preserved EF with mean EF 45%. Most of the patients were medicated by betablockers, angiotensin converting enzyme inhibitors and diuretics. In 26 patients (42%) there was evidence of pleural effusion by US imaging. During the study period, one of the 62 patients was hospitalized due to worsening HF (in total one admission) and two patients due to hypovolemia/pre renal failure. The 62 patients underwent 119 paired consultations, with mean ± SD 1.9 ± 1.0 visits per participants and, in total, 38 patients underwent a follow-up visit.

Reliability of medical history, clinical signs, physical findings and ultrasound

The nurse with access to ultrasound judged the patient having lower volume status in 18 visits and higher volume status in 26 visits, respectively.

The time consumption for the PSID ultrasound examination by the nurses was median (range) 5 (4-23) min. Both the clinical- and ultrasound examination were feasible in all patients (both first visit and follow-up) excluding missing data.

Prognostic influence of ultrasound findings, diuretic doses and NYHA-class

At 1 year follow-up 16 participants (25.8%) had been hospitalized due to any heart failure related cause, and all-cause mortality was 17.7% at 1 year.

In survival analyses NYHA class, diuretic dose and ultrasound measurements (1) semi quantitative inferior vena cava dimension and respiratory variation and 2) pleural effusion present or not) at first study visit were associated with outcome. With censor date April 30th 2015 and mean follow-up 605 days mortality was higher with higher NYHA-class (p=0.041) and diuretic dose (p=0.02). Total diuretic dose was calculated as equivalent to bumetanide regardless of type of diuretics used; 40 mg furosemide/50 mg aldosterone antagonist/12.5 mg hydrochlorothiazide/5 mg bendroflumethiazide were set equivalent to 1 mg bumetanide).

Presence of any amount of pleural effusion at first visit was near significant related to higher mortality during two year follow-up, p=0.07 (Supplemental Figure – Panel A).

Ultrasound findings of a dilated inferior vena cava with reduced inspiratory collapsibility (semi quantitative score ≥5 corresponding to dimension (≥17 mm + <35% collapsibility) or (>21 mm + <50% collapsibility) at first study visit was highly significant associated with increased mortality, p<0.001 (Supplemental Figure – Panel B).
Left Figure (A) indicate higher mortality (red curve) among those with any pleural effusion present at first study visit, p=0.007. Right Figure shows higher mortality among those with a dilated inferior vena cava with reduced inspiratory collapsibility present as dimension $\geq 17$ mm and $<35\%$ collapsibility or dimension $>21$ mm and $<50\%$ collapsibility corresponding to a cumulative semi quantitative score $\geq 5$, p<0.001.

Prediction of diuretic treatment
In unadjusted univariate analyses weight change, volume status assessed clinically and US assessment of the IVC and pleural cavities predicted dose adjustment of diuretics by the first visit.

In the manuscript we have described a semi quantitative score for IVC, ranging from 2-6 where 6 correspond to dimension $>21$ mm and inspiratory collapsibility $<35\%$. If weight change were scored $\pm 1$ for change $>1$ to $<4\%$ and $\pm 2$ for change $\geq 4\%$ (positive values if weight gain, negative values if weight loss) and otherwise score was 0.

The c-statistics (95% CI) for detection of increased diuretic dosage in the 57 visits where data for weight change were available were 0.77 (0.60-0.94) and 0.86 (0.74-0.98) IVC alone and the cumulative score of adding IVC and weight change, respectively. Thus, there was a near significant difference of adding weight change to IVC assessment. However, transforming the different variables according to how important they were for the three different outcomes of diuretic dosing (reduced, no change, increased) may introduce some
bias in the analyses. We find that the data from the regression analyses shown in Table 3 best describes the true story, as this correspond to the nurses decision about volume status after performing point of care ultrasound, and not to reclassification of data.
## Supplementary table. Basics and findings in 17 patients’ follow-up consultations where diuretic treatment differed between the teams

| Patient characteristics | IVC, mm/% collapsibility (baseline-FU) | Pleural effusion (baseline-FU) | NT-proBNP (baseline-FU) | Weight change | Change of oedema | Change NYHA | Volume status with (without) US | Diuretic dosing with (without) US |
|-------------------------|--------------------------------------|------------------------------|------------------------|--------------|-----------------|------------|-------------------------------|-----------------------------|
| W 71y, Isch HF, AFIB, EF 22%, TRsev. | 26/15% - 29/10% | R: 2.4-0 cm | 7640 - 7851 | +3.9 kg | Knee ↑ | 3 - 3 | ↑ (↑) | - (↑) |
| W 82y, Dias HF, AFIB, EF 45% | 23/26% - 24/29% | L: 1.5-2 cm, R: insign. - | 2275 - 2314 | +1.9 kg | Knee - | 2 - 2 | ↑ (↑) | ↑ (-) |
| W 82y, Dias HF, AFIB, EF 45% | 23/17% - 20/35% | L: 2.6-0 cm, R: insign. ↓ | 2363 - 2242 | -3.6 kg | Knee ↓ | 2 - 2 | - (↑) | ↓ (-) |
| W 80y, Dias HF, AFIB, EF 41% | 20/15% - 20/15% | - | 2012 - 2595 | +0.6 kg | None ↑ | 2 - 2 | - (-) | ↓ (-) |
| M 73y, Isch HF, SR, EF 22%, TRmod. | 31/13% - 28/14% | L: insign. - | 9999 - 9999 | -1.9 kg | Knee - | 2 - 2 | ↑ (↑) | - (↑) |
| M 85, Isch HF, SR, EF 44% | 13/69% - 9/90% | - | 3923 - 3740 | +0.1 kg | Ancle ↓ | 2 - 2 | ↓ (↓) | ↓ (↓) |
| W 49y, cong. HF, AFIB, EF na, TRsev. | 23/0% - 24/29% | R: 1.3-2.5 cm | 2997 - 2778 | -0.3 kg | Knee - | 4 - 4 | ↑ (-) | ↑ (↑) |
| M 80y, Isch HF, AFIB, EF 20% | 24/38% - 22/90% | - | 9999 - 9999 | -1.8 kg | Knee - | 3 - 3 | ↓ (↑) | ↓ (-) |
| W 72y, Isch HF, SR, EF 27% | 17/90% - 16/81% | - | 2650 - 2242 | +1.0 kg | None - | 2 - 2 | - (-) | - (↓) |
| M 80y, Isch HF, AFIB, EF 23%, TRsev. | 35/31% - 36/11% | R: 4.2-3.6, L: insign. - | 2895 - 2806 | +0.5 kg | Knee - | 2 - 2 | ↑ (↓) | - (↓) |
| M 80y, Isch HF, AFIB, EF 23%, TRsev. | 36/11% - 38/18% | R: 3.6-1.8, L: insign. ↓ | 2806 - 2925 | -1.6 kg | Knee - | 2 - 2 | ↑ (↓) | ↓ (-) |
| W 62y, HCM, SR, EF 41% | 23/70% - 21/90% | - | 1204 - 805 | +0.2 kg | None - | 2 - 2 | - (-) | ↓ (-) |
| W 35y, peripart., SR, EF 39% | 8/90% - 18/78% | - | 714 - 483 | -7.6 kg | None - | 2 - 1 | - (-) | - (↓) |
| W 71y, Isch HF, SR, EF 34% | 13/90% - 19/90% | R: 2.8-3.5, L: insign. - | 9999 - 9999 | +0.6 kg | Ancle ↓ | 2 - 2 | ↑ (↑) | ↑ (-) |
| M 38y, DCM, SR, EF 24% | 25/38% - 32/28% | - | * | +2.1 kg | None - | 2 - 2 | ↑ (↑) | ↑ (-) |
| M 90y, Isch HF, SR, EF 48% | 10/90% - 16/56% | - | * | -1.9 kg | Ancle ↓ | 2 - 1 | - (-) | - (↓) |
| M 72y, post radiation, AFIB, EF 30% | 14/90% - 14/79% | - | 1539 - 691 | -4.3 kg | None - | 2 - 2 | ↓ (↓) | - (↓) |

Abbreviations: AFIB; atrial fibrillation or atrial flutter, cong.; congenital, Dias; diastolic, DCM; dilated cardiomyopathy, EF; ejection fraction, FU; follow-up, HCM; hypertrophic cardiomyopathy, HF; heart failure, insign.; insignificant, IVC; inferior vena cava, Isch; ischemic, L; left, mod.; moderate, na; not applicable, peripart; peripartum cardiomyopathy, post radiation; heart failure post radiation, R; right, sev.; severe, TR;
tricuspid regurgitation, US; ultrasound, wo; without, ↑; hypervolemia (volume state) / increase (diuretic dose or oedema), ↓; normovolemia (volume state) / no change (diuretic dose or oedema), ↓; hypovolemia (volume state) / reduction (diuretic dose or oedema).